A commonly used antiseizure drug may cause serious metabolic problems in epilepsy patients, federal health regulators recently warned. According to the Food and Drug Administration, Zonegran and its generic counterpart zonisamide can create dangerous chemical imbalances in the blood that lead to difficulty breathing, irregular heart rhythms and other long-term health problems. Zonegran producer Eisai Inc. said it was currently considering labeling changes for the drug.